Comparative Pharmacology
Head-to-head clinical analysis: PREVACID NAPRAPAC 375 COPACKAGED versus ZEGERID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREVACID NAPRAPAC 375 COPACKAGED versus ZEGERID.
PREVACID NAPRAPAC 375 (COPACKAGED) vs ZEGERID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lansoprazole, a proton pump inhibitor, suppresses gastric acid secretion by inhibiting the gastric H+/K+-ATPase at the secretory surface of the gastric parietal cell. Naproxen, a nonsteroidal anti-inflammatory drug, inhibits cyclooxygenase (COX-1 and COX-2) reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Proton pump inhibitor that irreversibly inhibits the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, suppressing basal and stimulated gastric acid secretion.
One tablet (naproxen 375 mg / lansoprazole 15 mg) orally twice daily.
20 mg or 40 mg orally once daily before a meal.
None Documented
None Documented
Naproxen: 12-17 hours (mean 14 hours); allows twice-daily dosing. Lansoprazole: 1.5-2 hours (fast metabolizers) to 3-4 hours (slow metabolizers); clinically negligible due to irreversibly binding to proton pumps.
1.0–1.5 hours in plasma; however, the pharmacodynamic half-life is longer due to irreversible inhibition of H+/K+-ATPase; drug effect persists for 24 hours after single dose.
Naproxen: Approximately 95% excreted in urine as unchanged naproxen (10%) and metabolites (~60% 6-O-desmethylnaproxen and conjugates); <5% in feces. Lansoprazole: Primarily metabolized in liver; metabolites excreted in urine (14-23%) and feces (~22%).
Approximately 82% renal (as metabolites), 18% fecal (via bile); less than 1% unchanged in urine.
Category C
Category C
Proton Pump Inhibitor/NSAID Combination
Proton Pump Inhibitor